Innovation Technologies, Inc. Announces Creation Of Distinguished Medical Advisory Board

ATLANTA, Oct. 13, 2014 /PRNewswire/ -- Innovation Technologies, Inc., and its operating subsidiary, IrriMax Corporation, announce the formation of its first Medical Advisory Board. The Board is comprised of medical professionals with extensive expertise regarding surgical site infections (SSI) and related issues. IrriMax manufactures the company's flagship product, IrriSept, the first and only FDA-cleared wound debridement and cleansing system containing 0.05% Chlorhexidine Gluconate (CHG).

The Medical Advisory Board will help advance the company's mission to create products that significantly reduce the occurrence of SSIs and help drive an evidence-based, standard of care for surgical irrigation. The board will help define the company's clinical programs, as well as contribute to its research and development initiatives.

"The creation of a Medical Advisory Board is essential to our future success. Scientific and clinical evidence is at the core of our approach to reduce SSIs, improve patient outcomes and reduce hospital costs," said Gareth Clarke, chairman and CEO of Innovation Technologies, Inc. and IrriMax Corporation. Clarke added, "The experience and insight of this distinguished board will contribute greatly to directing the company's scientific and clinical strategy."

Donald Fry, MD, former President of the Surgical Infection Society and acknowledged authority on the subject of SSIs, will serve as the Board's chair. Dr. Fry is Executive Vice President of Clinical Outcomes Management at Michael Pine and Associates, Adjunct Professor of Surgery at Northwestern University, and Professor Emeritus, Department of Surgery at the University of New Mexico School of Medicine. At Michael Pine and Associates, Dr. Fry provides clinical leadership in analyzing and evaluating clinical performance, guiding quality improvement, and creating incentives for coordinated, cost-effective care. Dr. Fry is working with Carolyn Twomey, Vice President of Clinical Affairs for IrriMax, to develop a phase IV, multi-center, prospective, randomized, controlled clinical study to compare the IrriSept system to the current standard of care on the incidence of surgical site infections in patients with abdominal trauma or acute surgical abdomen.  

"I am pleased to be working with a company committed to providing independent clinical evidence on the performance of its products," stated Dr. Fry. "As chairman, I hope to contribute to this important effort to help reduce SSIs and improve patient outcomes."

Additional members of this Medical Advisory Board include:

Charles Edmiston, Jr., PhD, SM (ASCP), CIC (CHIC), Professor of Surgery and Hospital Epidemiologist at Froedtert Hospital, and Director of Surgical Microbiology Research Laboratory, Department of Surgery at the Medical College of Wisconsin.

Sander S. Florman, MD, Professor of Surgery and Director of the Recanati/Miller Transplantation Institute at The Mount Sinai Medical Center. Dr. Florman is a leading expert in liver transplantation.

Philip S. Barie, MD, Professor of Surgery at Weill Cornell Medical College and attending surgeon at New York-Presbyterian/Weill Cornell Medical Center specializing in high-risk surgery, trauma, surgical critical care, surgical infections, hernia repair, and gastrointestinal surgery. Dr. Barie also serves as the editor of Surgical Infections.

Martin Croce, MD, Professor of Surgery and Division Chief of the Trauma Division at The University of Tennessee Health Science Center.

Jaime Sanchez, MD, Assistant Professor of Surgery, and colon and rectal surgeon at the College of Medicine, University of South Florida.

About IrriMax Corporation
Founded in 2003, IrriMax Corporation is a medical device company whose corporate goals are focused on treating and preventing infections, reducing healthcare costs, improving patient outcomes and increasing the safety of healthcare professionals. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information, visit www.IrriSept.com

MEDIA CONTACT
IrriMax
Kelly Herman
770-807-3355
pr@irrimax.com

SOURCE Innovation Technologies Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news